Matt Davis joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is the associate director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and biomarker validation efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group. He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute.